Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model
Shock, Volume 2, No. 1, Year 1994
Notification
URL copied to clipboard!
Description
Timely intervention in recurrent episodes of sepsis poses a major problem in intensive care, because the diagnosis is often made after the onset of sepsis, delaying the initiation of treatment. There are only a few animal models that cover this situation. We have developed a baboon model of recurrent bacteremia (3 × 2 h intravenous infusion of 1 × 108 CFU Escherichia coli/kg), which leads to late organ failure. In this model (tested on 16 animals) we began anti-tumor necrosis factor antibody treatment (BAYX 1351; Bayer AG, 7.5 mg/kg or saline placebo) after the first bacteremic episode (+4 h), which significantly (p < .05) protected animals from death, none out of eight (100% survival), in the treatment group in contrast to four animals out of eight died (50% survival) in the placebo group. This effect was also reflected in improved organ function and in attenuated cytokine and plasminogen activator inhibitor release. From these studies we conclude that the delayed application of anti-tumor necrosis factor antibodies in recurrent bacteremia is a powerful tool for preventing septic death. © 1994 The Shock Society.
Authors & Co-Authors
Schlag, Günther
Austria, Vienna
Ludwig Boltzmann Institut Für Experimentelle Und Klinische Traumatologie
Redl, Heinz
Austria, Vienna
Ludwig Boltzmann Institut Für Experimentelle Und Klinische Traumatologie
Davies, James
South Africa
Roodeplaat Research Laboratories
Haller, Ingo
Germany, Leverkusen
Bayer ag
Statistics
Citations: 38
Authors: 4
Affiliations: 3
Identifiers
Doi:
10.1097/00024382-199407000-00002
ISSN:
10732322
e-ISSN:
15400514
Research Areas
Cancer
Study Design
Randomised Control Trial